Clinical Trial

Caudal Block vs Retrolaminar Block on Analgesic Consumption in Undescended Testis Surgeries

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 18, 2025 (before its estimated December 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study compares the postoperative analgesic effectiveness of Caudal Block (CB) and Retrolaminar Block (RLB) in pediatric patients undergoing undescended testis surgeries. Both techniques aim to manage pain effectively and reduce reliance on systemic analgesics, improving recovery and minimizing complications. The double-blind, randomized controlled trial will include 1-7-year-old ASA I-II patients at two hospitals. Patients with specific contraindications (e.g., spinal anomalies, allergies, or infections) will be excluded. Randomization divides participants into two groups (CB and RLB), with pain assessments performed using the FLACC pain scale by a blinded nurse. Procedures: CB: 0.125% bupivacaine (1 mL/kg, max 20 mL) injected into the sacral canal under ultrasound guidance. RLB: 0.25% bupivacaine (0.1 mL/kg) injected into the retrolaminar space at the L4 level under ultrasound guidance. Postoperative pain will be evaluated at various intervals (30 minutes to 24 hours). Intravenous paracetamol or tramadol will be administered based on pain scores. The study aims to compare pain scores, time to first analgesic requirement, and postoperative complications, contributing valuable data on these two regional anesthesia techniques in pediatric surgery.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-05.
Status change: Not Yet Recruiting → Recruiting 2025-02-16
Trial Details
NCT Number NCT06725862
Lead Sponsor Kanuni Sultan Suleyman Training and Research Hospital
Conditions Post Operative Pain
Enrollment 60 participants
Start Date 2024-12-15
Primary Completion 2025-12-15 (estimated)
Study Completion 2025-12-16 (estimated)
Updated on ClinicalTrials.gov 2025-02-18